Protalix BioTherapeutics (PLX) EBIT Margin (2010 - 2026)

Protalix BioTherapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 62.65% for Q1 2026.

• On a quarterly basis, EBIT Margin rose 10364.0% year-over-year to 62.65% in Q1 2026; TTM through Mar 2026 was 25.91%, a 1817.0% increase from a year earlier, with the FY2025 full-year figure at 10.43%, down 1776.0% from the prior year.
• EBIT Margin grew to 62.65% in Q1 2026 per PLX's latest filing, from 51.06% in the prior quarter.
• Across five years, EBIT Margin topped out at 62.65% in Q1 2026 and bottomed at 129.56% in Q1 2024.
• The 5-year median for EBIT Margin is 18.24% (2023), against an average of 15.33%.
• Across the five-year window, EBIT Margin jumped 12133 bps in 2023 and sank 10392 bps in 2024, its largest moves.
• Year by year, EBIT Margin stood at 28.95% in 2022, then slumped by 85 bps to 53.55% in 2023, then surged by 174 bps to 39.57% in 2024, then tumbled by 229 bps to 51.06% in 2025, then surged by 223 bps to 62.65% in 2026.
• Per Business Quant, the three latest PLX EBIT Margin figures stand at 62.65% (Q1 2026), 51.06% (Q4 2025), and 11.94% (Q3 2025).